Skip to content
MetaGene Pty Ltd

Validated, Certified & Low Cost Pathology, Histology & Cancer Research Products

  • Home
  • Manufacturers
    • Applied Spectral Imaging
    • Biocare Medical
    • Empire Genomics
    • GenomeMe
    • Horizon Diagnostics
    • Interscience
    • Nordic BioSite
    • Santa Cruz Biotechnology
    • Ultivue
  • Products
    • Antibodies
    • Bag Mixer
    • Colony Counters
    • Decloaking Chamber
    • FISH Imaging and Analysis
    • FISH Probes
    • GenASIs Pathology Suite
    • Gravimetric Dilutor
    • HPV Detection Kits
    • IHC Automated Stainer
    • IHC Detection Kits
    • IHC FISH Controls
    • Peristaltic Pumps
    • PCR Reagents
    • Reference Standards
    • Slide Drying Oven
  • Company
    • About Us
    • Community
      • Triathlete Youth Sponsorships
      • Triathlete Youth Ambassador Program
    • Compliance
    • Media
    • News
      • Advanced understanding of cancer progression in circulating tumor cells through the use of multiplexed imaging technology
    • Terms and Conditions
  • Contact Us
  • Home
  • Manufacturers
    • Applied Spectral Imaging
    • Biocare Medical
    • Empire Genomics
    • GenomeMe
    • Horizon Diagnostics
    • Interscience
    • Nordic BioSite
    • Santa Cruz Biotechnology
    • Ultivue
  • Products
    • Antibodies
    • Bag Mixer
    • Colony Counters
    • Decloaking Chamber
    • FISH Imaging and Analysis
    • FISH Probes
    • GenASIs Pathology Suite
    • Gravimetric Dilutor
    • HPV Detection Kits
    • IHC Automated Stainer
    • IHC Detection Kits
    • IHC FISH Controls
    • Peristaltic Pumps
    • PCR Reagents
    • Reference Standards
    • Slide Drying Oven
  • Company
    • About Us
    • Community
      • Triathlete Youth Sponsorships
      • Triathlete Youth Ambassador Program
    • Compliance
    • Media
    • News
      • Advanced understanding of cancer progression in circulating tumor cells through the use of multiplexed imaging technology
    • Terms and Conditions
  • Contact Us

Category Archives: Suppliers

  • Home
  • Archive by category "Suppliers"

COVID-19 Lockdowns – Melbourne & Victoria

MetaGene would like to assure our Melbourne and Regional Victoria customers that we remain open for business and will continue to supply products throughout the COVID-19 lockdowns.

Our main warehouse is located in Queensland and is fully operational.

To date our overseas manufacturers (including Biocare Medical, Horizon Discovery, Santa Cruz Biotechnology, Applied Spectral Imaging, Interscience and Ultivue) as well as our supply chain partners including FedEx, DHL and StarTrack have continued to maintain operations.

We are experiencing some delivery delays and appreciate your patience at this time.

Read More

  • 5 Aug, 2020
  • (0) Comments
  • By metagene
  • COVID-19, Lockdowns, Products, Suppliers

COVID-19 and Continuity of Supply in Australia

MetaGene has been monitoring developments with regards to the novel coronavirus (COVID-19), specifically with regards to continuing the supply of products to our customers. We are working closely with our overseas manufacturers, including Biocare Medical, Horizon Discovery and Santa Cruz Biotechnology, as well as supply chain partners including FEDEX and StarTrack to ensure continuity of supply, however, this is an unprecedented and dynamic situation.

In the short term, we do not anticipate supply chain disruption.

We reserve the right to limit order quantities based on demand so that we can ensure supply chain continuity for products used in clinical patient testing. As the situation evolves, we will endeavour to communicate relevant changes as soon as possible.

 

Read More

  • 27 Mar, 2020
  • (0) Comments
  • By metagene
  • COVID-19, Products, Suppliers
TGA Approval For New Digital Pathology System, MetaGene GenASIs System, HiPathPro, PathFusion, Applied Spectral Imaging, Cancer Diagnosis, Pathology

TGA Approval For New Digital Pathology System

https://metagene.com.au/wp-content/uploads/2017/10/MetaGene_7NewsBrisbane_26102017.mp4

 

Diagnostic digital pathology system improving the landscape of cancer diagnosis

In an Australian first, the Federal Government has granted TGA approval for a diagnostic digital pathology system set to radically improve the outlook for cancer patients through rapid and accurate diagnosis.

MetaGene has received TGA class III Medical Device certification for GenASIs – a groundbreaking diagnostic platform offering quantitative, accurate and validated analysis of patient samples in a clinical setting.

MetaGene Managing Director Richard Holder and Dr Eugen Petcu today unveiled the only fully operational GenASIs system currently in Australia, which is located at the Menzies Health Institute.

The Menzies Centre, Griffith University. Pictured: Richard Holder - MetaGene Managing Director, Dr Eugen Petcu of the Mensies Centre along with Melissa Whitehouse of MetaGene. Photography: David Clark Photography
The Menzies Centre, Griffith University. Pictured: Richard Holder – MetaGene Managing Director, Dr Eugen Petcu of the Mensies Centre along with Melissa Whitehouse of MetaGene. Photography: David Clark Photography

Mr Holder says the TGA class III certification demonstrates the system’s robust design and extensive validation as a clinical device which will alter the landscape of diagnostic technology, leading to a better outcome for patients.

“GenASIs provides higher diagnostic confidence and uncompromising result standardisation, replacing previous indicative diagnosis,” he said. “This highly anticipated system can test thousands of cells in infinitely less time with a more accurate outcome than any other system currently in the market. This not only means greater efficiency, quality control and cost savings for laboratories – it means cancer patients will have the chance to receive more personalised treatments plans based on a more accurate diagnosis.”

MetaGene is the sole Australian distributor of the GenASIs system, which is now available to hospitals and laboratories across the country.

Global leader in computer-assisted biomedical imaging, Applied Spectral Imaging (ASI), who designed the GenASIs technology, launched an upgraded GenASIs diagnostic system earlier this month at the College of American Pathologists meeting in Orlando FL.

Dr Petcu, associated with Griffith University and the Menzies Health Institute Queensland says GenASIs, which is also approved by the FDA and is currently implemented in clinical settings in the USA, Canada and Europe, is an advanced workflow solution based on revolutionary technology with industry leading applications.

“This is the beginning of an exciting new era in diagnostic technology and I am very grateful to have access to the only fully functioning GenASIs system currently in Australia for my own cancer research,” he said. “Through exceptional image quality and precise computer-assisted analysis, this technology provides uncompromising standardisation of results at the click of a button, providing a quality baseline for consistent accurate analysis of cancer cells. This counteracts the inevitable variability that comes with manual analysis.”

The Australian Bureau of Statistics estimates 17, 730 new cases of breast cancer will be diagnosed in 2017. In a study of Ki-67 – a cancer aggression marker that indicates how urgently patients require treatment – there was a 6 per cent difference between manual analysis and image analysis on the GenASIs system. The manual analysis scored lower Ki-67 results. This diagnosis may inadvertently mean those patients could be less likely to receive urgent clinical attention. After comparing the two techniques pathologists reviewed their diagnosis, changing it to reflect the GenASIs system.

Dr Petcu says the GenASIs system functions as an adjunct tool to the microscope allowing the statistical analysis of thousands of cells in relevant tumour regions to be conducted digitally.

“The system is so accurate that it can potentially prevent the need for pathologists to send samples for further testing, significantly improving the turn-around time for results,” he said. “With a faster, more accurate analysis, the patient can feel confident in their diagnosis and their treatment pathway can be tailored specifically for them.”

ABOUT ASI

ASI is a global leader in the development of biomedical imaging solutions, supporting fluorescent, Brightfield and spectral image-acquisition, for the Pathology and Cytogenetics markets.

HiPath Pro™ and PathFusion™, powered by GenASIs™, are automated imaging platforms that provide advanced diagnostic aids for pathologists, with reproducible and standardized results. ASI platforms support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any laboratory.

ASI’s applications are FDA cleared for BandView, FISHView, CEP XY, UroVysion, ALK, HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67.

ASI serves clinical laboratories, life science companies and research institutions in over 50 countries.

 


 

DOWNLOADS

To save to your computer: right click, “Save Link As” and choose your local destination.


Media Release – GenASIs Improves Diagnosis For Cancer Patients


Quantitative Image Analysis of Ki67 Immunohistochemistry compared with manual pathologist analysis in Breast Cancer


Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry


MetaGene Presents: The Complete Digital Pathology System


Every Diagnosis Counts: HiPath Pro Advanced Digital Pathology (ASI)


Laboratory Investigation: HER2 M-Scores in Gastric/Gastroesophageal Junction Adenocarcinomas: Comparison of Digital Image Analysis and Pathologist Interpretation


Fact Sheet & Terms Used

  • 26 Oct, 2017
  • (0) Comments
  • By metagene
  • ASI, GenASIs System, Products, Suppliers
New Supplier Nordic BioSite, MetaGene Pty Ltd, Pathology, Histology, Cancer Research, MetaGene, Nordic Biosite

MetaGene Announces New Supplier – Nordic BioSite

New Supplier Nordic Biosite, MetaGene Pty Ltd, Pathology, Histology, Cancer Research, MetaGene, Nordic Biosite

We are excited to announce that we are now the Australian distributer of Nordic Biosite.

Nordic Biosite Boast a 1,500,000-item product catalogue covering diagnostic antibodies to life science research reagents.

Now in business for nearly 20 years, Nordic BioSite is recognised as a leader in supply of products for research and diagnostic, Immunology and Molecular Biology, to Pharmaceutical, Biotech, Diagnostic and to academic researchers.

Continuously, Nordic BioSite introduces many novel products as a result of the research and development with our partners and the feed back from our customers. Through the development, manufacturing, marketing and distribution of our products our aim is to facilitate your research.

  • 1 Jul, 2017
  • (0) Comments
  • By metagene
  • Nordic BioSite, Suppliers
Recent Posts
  • P40 ANTIBODY PROMOTION
  • INTERSCIENCE – FLEXIPUMP PRO $4,999*
  • Go FISH-ing with us! – 20% discount off FISH Probes
  • Discounted Decloaking Chamber™ NxGen
  • The Cleanest SOX – 25% Cheaper!
Categories
  • Antibodies
  • ASI
  • Biocare Medical
  • Cancers
  • Charity
  • COVID-19
  • Digital Pathology
  • GenASIs System
  • Horizon Discovery
  • Lockdowns
  • Nordic BioSite
  • Products
  • Sale
  • Santa Cruz Biotechnology
  • Suppliers
  • Training
GET IN TOUCH!

You can always reach us.

MetaGene prides itself on it’s exceptional customer service.

 

Hours of Operation:

8am – 8pm AEST.

 

CONTACT US

Address:

Level 34, 1 Eagle Street

Brisbane QLD 4000

Phone: Free Call 1800 788 498

Fax: 1300 307 595

Send an email:

© 2020 MetaGene Pty Ltd. All Rights Reserved.